PEPPERLIME HEALTH ACQUISITION CORPORATION UNDERWRITING AGREEMENTUnderwriting Agreement • October 12th, 2021 • PepperLime Health Acquisition Corp • Blank checks • New York
In June 2021, the Company sold 5,750,000 Class B ordinary shares (the “Founder Shares”) to PepperOne LLC (the “Sponsor”) for $25,000 pursuant to a Securities Subscription Agreement, dated as of June 30, 2021 (the “Sponsor Subscription Agreement”) in substantially the form filed as an Exhibit 10.5 to the Registration Statement. On September 28, 2021, the Sponsor effected a surrender of Founder Shares to the Company for no consideration, resulting in a decrease in the total number of Class B ordinary shares outstanding from 5,750,000 to 4,312,500. In September 2021, the Sponsor also transferred the aggregate of 923,000 Founder Shares to certain anchor investors (the “Anchor Investors”) under the investment agreements in substantially the form filed as Exhibit 10.8 to the Registration Statement. Up to 562,500 of the Founder Shares are subject to forfeiture by the Sponsor depending on the extent to which the Underwriters’ over-allotment option is exercised. Except as described in the Regis
PepperLime Health Acquisition Corporation 548 Market Street, Suite 97425 San Francisco, California 94104Underwriting Agreement • October 12th, 2021 • PepperLime Health Acquisition Corp • Blank checks
This letter (this “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between PepperLime Health Acquisition Corporation, a Cayman Islands exempted company (the “Company”), and Oppenheimer & Co., Inc. (the “Underwriter”), relating to an underwritten initial public offering (the “Public Offering”), of up to 17,250,000 of the Company’s units (including up to 2,250,000 units that may be purchased to cover over-allotments, if any) (the “Units”), each comprised of one Class A ordinary share of the Company, par value $0.0001 per share (each an “Ordinary Share”), and one-half (1/2) of one redeemable warrant (each whole warrant, a “Warrant”). Each whole Warrant entitles the holder thereof to purchase one Ordinary Share at a price of $11.50 per share, subject to adjustment, as described in the Prospectus (as defined below). The Units will be sold in the Public Offering pursuant to a registration statement
